Keywords: nicox, begins, phase, iia, hct-1026, commenced, clinical

NicOx begins Phase IIa with HCT-1026

Article | 20 December 1999

Print This

NicOx has commenced a Phase IIa clinical program of its lead compound,HCT-1026, in patients with Paget's disease. HCT-1026 is ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in